Skyhawk Therapeutics, Inc. has expanded its collaboration with Biogen, extending Biogen's exclusive license to worldwide rights beyond the original research-stage therapeutic candidates for the treatment of conditions including multiple sclerosis (MS), spinal muscular atrophy (SMA) and additional neurological disorders, leveraging Skyhawk's SkySTAR technology platform.
Skyhawk receives an upfront payment from Biogen and may receive potential future milestone payments and royalties.
"Biogen is a leading neuro-focused biopharmaceutical company with a compelling history of drug development across a range of challenging conditions," said Bill Haney, co-founder and chief executive officer of Skyhawk. "Their strong scientific culture has already produced a series of leading global therapeutics and our work together to date has gone very well. We are excited to expand our opportunity to work together to help more patients with challenging unmet medical needs."
Breaking News
Skyhawk, Biogen Expand Alliance in Neurological Disorders
Skyhawk receives an upfront payment and is eligible for future milestones and royalties
07.08.19
Related Breaking News
-
Breaking News | Drug Development | Industry News
Bristol Myers Squibb Expands at Cambridge Crossing
Adds remaining 113,000 square feet to its initial lease at 250 Water Street.Kristin Brooks 04.16.21
-
Breaking News | Drug Development | Industry News
Amgen Completes Five Prime Acquisition
Gains pipeline of immuno-oncology and targeted cancer therapies, including a Phase 3 trial-ready, first-in-class program for gastric cancer.Kristin Brooks 04.16.21
-
Breaking News | Drug Development | Industry News
BioVersys Gets EIB Funds to Address Antimicrobial Resistance
Financing supports development of BioVersys’ breakthrough hospital antibiotic therapy targeting Acinetobacter baumanniiKristin Brooks 04.14.21
-
Breaking News | Clinical Trials | Drug Development | Trials & Filings
FDA Accepts Airway Therapeutics’ IND for COVID Treatment
To initiate a Phase 1b trial to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.Kristin Brooks 04.12.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Sanofi Acquires Tidal Therapeutics
Gains novel mRNA-based technology with research capabilities in immuno-oncology and inflammatory diseases, with potential in other disease areas.Kristin Brooks 04.12.21
-
Analytical Services | Breaking News | Clinical Trial Materials | Drug Development | Industry News
Ascendia Pharmaceuticals Poised for Expansion
CDMO secures growth equity investment from Signet Healthcare Partners.Tim Wright, Editor, Contract Pharma 04.09.21
-
Bio News | Breaking News | Collaborations & Alliances | Drug Discovery | Industry News | Information Technology
Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
Supporting R&D optimization of next-generation biopharmaceuticals with digital technology and drug discovery platform.Tim Wright, Editor, Contract Pharma 04.07.21
-
Breaking News | Collaborations & Alliances | Drug Delivery | Drug Development | Industry News
Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
Work together to develop and commercialize CHI’s novel dry-powder inhaler product.Charles Sternberg, Assistant Editor 04.07.21
-
Breaking News | Clinical Trials | Drug Development | Industry News
Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment
To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.Kristin Brooks 04.06.21
-
Breaking News | Clinical Trials | CRO News | Drug Development
Moleculin Selects IQVIA Biotech to Advance COVID Treatment
IQVIA to manage the company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.Kristin Brooks 04.06.21
-
Breaking News | Drug Development
Servier Acquires Agios Pharmaceuticals’ Oncology Portfolio
Expands its oncology leadership capabilities in the U.S.Charles Sternberg, Assistant Editor 04.01.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.Kristin Brooks 04.01.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Ajinomoto, Bright Peak Enter Immunocytokines Research Pact
Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.Kristin Brooks 03.30.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Facilities | Industry News
Chime Biologics Expands CDMO Capabilities
Completes $190 million financing round to accelerate capacity expansion.Tim Wright, Editor, Contract Pharma 03.29.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development | Industry News
CyanVac and Exothera Enter COVID-19 Vaccine Partnership
CDMO Exothera selected for the development and GMP manufacturing of intranasal vaccine candidate for Phase III clinical trial is Europe and the U.S.Tim Wright, Editor, Contract Pharma 03.25.21
